RVPH REVIVA PHARMACEUTICALS HOLD...

Nasdaq revivapharma.com


$ 0.48 $ -0.03 (-6.29 %)    

Thursday, 20-Nov-2025 12:35:28 EST
QQQ $ 590.62 $ -21.13 (-3.45 %)
DIA $ 458.42 $ -8.26 (-1.77 %)
SPY $ 656.28 $ -16.73 (-2.49 %)
TLT $ 89.35 $ 0.37 (0.42 %)
GLD $ 372.43 $ -2.73 (-0.73 %)
$ 0.4981
$ 0.51
$ 0.49 x 300
$ 0.50 x 1,500
$ 0.48 - $ 0.52
$ 0.25 - $ 4.28
2,792,929
na
57.31M
$ 0.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 04-02-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 04-15-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-16-2022 03-31-2022 10-Q
16 03-15-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-17-2021 03-31-2021 10-Q
20 03-22-2021 12-31-2020 10-K
21 01-14-2021 11-30-2020 10-Q
22 10-14-2020 08-31-2020 10-Q
23 07-07-2020 05-31-2020 10-Q
24 05-04-2020 02-29-2020 10-K
25 01-10-2020 11-30-2019 10-Q
26 10-08-2019 08-31-2019 10-Q
27 07-03-2019 05-31-2019 10-Q
28 05-22-2019 02-28-2019 10-K
29 01-09-2019 11-30-2018 10-Q
30 10-11-2018 08-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 d-boral-capital-maintains-buy-on-reviva-pharmaceuticals-maintains-2-price-target

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $2 price target.

 reviva-pharmaceuticals-q3-eps-006-beats-010-estimate

Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate o...

 d-boral-capital-maintains-buy-on-reviva-pharmaceuticals-maintains-2-price-target

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $2 price target.

 hc-wainwright--co-maintains-buy-on-reviva-pharmaceuticals-lowers-price-target-to-4

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and lowers the ...

 this-vse-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 chardan-capital-initiates-coverage-on-reviva-pharmaceuticals-with-buy-rating-announces-price-target-of-2

Chardan Capital analyst Rudy Li initiates coverage on Reviva Pharmaceuticals (NASDAQ: RVPH) with a Buy rating and announces ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION